Vitality Watch

Dossier biorxiv observational 14-sep-2026
Human cohort, case-control, or epidemiological association

The Alpha-1 Antitrypsin Z-allele associates with sarcopenia in the UK Biobank

Key claim: The SERPINA1 Z allele is associated with dose-dependent lower muscle mass and higher sarcopenia risk independent of lung and liver function, modestly mediating increased mortality.

Abstract

BackgroundSarcopenia is common in chronic obstructive pulmonary disease (COPD) and contributes to adverse outcomes. Alpha-1 antitrypsin deficiency (AATD) is the most common genetic cause of COPD, but its impact on skeletal muscle remains to be determined.

MethodsWe performed a retrospective analysis of 487,207 participants in the UK Biobank with available SERPINA1 genotyping. Associations between AAT genotypes and measures of skeletal muscle mass were determined using multivariable linear and logistic regression models. Models adjusted for age, sex, smoking status, genetic principal components, lung function (FEV% predicted), and liver fibrosis risk (FIB-4). We determined that the Z-allele was associated with sarcopenia and mortality using regression models and mediation analysis.

ResultsCompared with PIMM individuals, carriers of the Z allele (PIMZ, PISZ, PIZZ) demonstrated significantly lower fat free mass index (FFMI) and appendicular skeletal muscle index (ASMI), as well as higher odds of sarcopenia by binary definition. Associations persisted after adjustment for lung and liver function. A dose-dependent relationship was observed, with the greatest reductions in muscle mass and highest sarcopenia associated with PI*ZZ individuals (adjusted OR for FFMI-defined sarcopenia 2.02, 95% CI 1.16-3.32). Each additional Z allele was associated with increased mortality risk (adjusted OR 1.09, 95% CI 1.02-1.16), with sarcopenia mediating a modest proportion ([~]2.6%) of this association.

Conclusions.The SERPINA1 Z allele is associated with reduced muscle mass and increased risk for sarcopenia independent of lung and liver disease. Our findings expand the phenotypic spectrum of AATD-related diseases to include skeletal muscle as a modifiable target for intervention.

Why this matters

Sarcopenia risk stratification has largely been built from age, activity, nutrition, and body composition; a common protease-inhibitor variant (SERPINA1 Z) acting on muscle independently of its known lung and liver effects broadens the etiologic map into monogenic territory. If replicated, it identifies AATD carriers as a genetically enriched subgroup where the standing resistance-training case may need earlier or intensified application, though this remains an association without intervention data.

Source

Link

Briefing card

The Alpha-1 Antitrypsin Z-allele associates with sarcopenia in the UK Biobank
Stage: observational · biorxiv · 14-sep-2026

If you carry the SERPINA1 Z allele (alpha-1 antitrypsin deficiency), this UK Biobank analysis links your genotype to lower muscle mass and higher sarcopenia risk even without lung or liver disease.

The SERPINA1 Z allele is associated with dose-dependent lower muscle mass and higher sarcopenia risk independent of lung and liver function, modestly mediating increased mortality.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.64898/2026.09.12.26362905

build build 880 · 2bcef25 · 2026-11-18